ORGANOGENESIS HOLDINGS INC.

ORGO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $37.0M $861.0K $4.9M $15.5M $94.2M $17.2M $-38.7M $-64.8M
Depreciation & Amortization $15.3M $13.6M $10.4M $5.8M
Depreciation $15.3M $13.6M $10.4M $5.8M $5.8M $4.4M $3.8M $3.3M
Amortization $3.3M $3.4M $4.9M $4.9M $4.9M $3.7M $6.0M $3.7M
Stock-Based Compensation $13.3M $10.6M $9.0M $6.6M $3.9M $1.7M $936.0K $1.1M
Net Cash from Operating Activities $-10.3M $14.2M $30.9M $24.9M $62.0M $5.5M $-33.5M $-60.6M
Investing Activities
Capital Expenditures $14.2M $10.0M $24.4M $33.9M $31.2M $17.7M $6.0M $1.9M
Business Acquisitions $5.8M
Net Cash from Investing Activities $-14.2M $-10.0M $-24.4M $-33.9M $-31.2M $-23.5M $-6.2M $-1.9M
Financing Activities
Dividends Paid
Stock Repurchases $25.5M $0 $0
Net Cash from Financing Activities $-17.4M $27.6M $-5.5M $-2.2M $-1.0M $42.5M $78.7M $81.5M
Net Change in Cash $-41.8M $31.8M $1.0M $-11.2M $29.7M $24.4M $39.0M $19.0M
Free Cash Flow $-24.5M $4.2M $6.6M $-9.0M $30.8M $-12.2M $-39.5M $-62.5M
← Newer Page 1 of 2 Older →